Tivicay

What is it?

Composition

Active ingredient: dolutegravir (as dolutegravir sodium) in film-coated tablets. Excipients may include tablet core fillers/binders and a film-coating; exact inactive ingredients depend on tablet strength and manufacturer specification.

How to use?

Tivicay is taken by mouth as a film-coated tablet. On this page, Tivicay is supplied as tablets in the 50 mg strength, and it is swallowed with water. Tivicay can be taken with or without food, which helps many people stick to a consistent routine. In clinical practice, the best time is the time you can keep every day, because adherence is what drives viral suppression.

Typical administration points patients find useful:

• Take Tivicay at the same time daily when used in once-daily regimens.
• Swallow the tablet whole with water.
• Food is optional, but consistency helps if nausea appears.
• Separate from certain supplements (details in interactions below).
• If vomiting occurs soon after a dose, contact your HIV clinic for a plan tailored to your regimen.

Tivicay Dosage and Adjustments for Impairment

For many adults, dolutegravir-containing regimens use once-daily dosing, while some treatment-experienced situations (or interaction-driven situations) use twice-daily dosing. Dose selection also changes when Tivicay is combined with certain enzyme-inducing medicines (for example, some anticonvulsants), because they can lower dolutegravir levels and reduce antiviral activity. Renal impairment usually does not require a dolutegravir dose adjustment, since dolutegravir is not primarily cleared unchanged by the kidneys, but people with severe renal impairment need careful regimen selection if other drugs in the combination are renally cleared. Hepatic impairment can change exposure in advanced liver disease, so clinicians individualise therapy in moderate-to-severe hepatic impairment and monitor more closely for adverse effects and lab changes ^[2].

How does it work?

• Route: oral (tablets), swallow with water.
• Adults and adolescents ≥12 years and ≥40 kg (treatment-naive): 50 mg once daily.
• Adults and adolescents ≥12 years and ≥40 kg (with certain resistance or when used with enzyme inducers): 50 mg twice daily.
• Children (weight-based dosing): use the prescribed tablet strength to match the mg per kg regimen; dose is typically once daily or twice daily depending on age/weight and interacting medicines.
• With or without food: may be taken with or without meals; if taken with polyvalent cations (antacids/iron/calcium), separate per prescriber directions.
• Timing: take at the same time each day.
• Duration: long-term continuous therapy as prescribed; do not stop without clinician advice.

Indications

Tivicay is used for the treatment of HIV-1 infection. It is taken as part of combination antiretroviral therapy, meaning Tivicay is paired with other antiretroviral drugs to suppress viral replication and reduce viral load. For many patients, the practical goal is an undetectable viral load with stable or improving CD4 cell counts, because that correlates with lower risk of opportunistic infections over time. Tivicay is not used alone as monotherapy for HIV, because combination treatment is the standard approach to prevent treatment failure and resistance.

Treatment choice still depends on the full regimen. Drug interactions matter.

Comparison

Tivicay (dolutegravir) sits in the integrase inhibitor group, alongside other integrase inhibitors such as bictegravir, elvitegravir, and raltegravir. Integrase inhibitors are widely used because they suppress HIV efficiently and tend to be easier to tolerate than some older drug classes, though each option has its own interaction profile and tolerability pattern. Tivicay may also be prescribed as part of fixed-dose combinations such as abacavir/dolutegravir/lamivudine (Triumeq), while other regimens may include drugs from older classes like efavirenz (found in older combinations such as Atripla) or nucleotide/nucleoside backbones like Truvada in certain regimen designs.

A nuance clinicians consider: resistance patterns and prior treatment history shape the choice. Another: elvitegravir often appears in boosted combinations, which increases interaction complexity compared with unboosted dolutegravir regimens.

Contraindications

• Known hypersensitivity to dolutegravir or any component of Tivicay
• Concomitant use of dofetilide (contraindicated due to increased dofetilide exposure and risk of serious arrhythmias)
• Breastfeeding (lactation)

Not recommended for

Avoid Tivicay if you have ever had an allergic reaction to dolutegravir or any ingredient in the tablet. Do not take it if you use dofetilide for heart rhythm problems, because the combination can be dangerous. Breastfeeding is generally not advised in this context and should be discussed with your HIV team.

If you are pregnant, have hepatitis B or C, or have severe kidney or liver disease, you may still be able to use Tivicay but you will typically need closer monitoring and an individualised regimen plan.

Side effects

Most people tolerate Tivicay well, but side effects do happen, especially in the first weeks.

Common side effects reported with dolutegravir-containing therapy can include:

• Headache
• Insomnia or vivid dreams
• Nausea, stomach upset, diarrhoea
• Dizziness
• Fatigue

Side effects that need urgent medical assessment:

• Signs of hypersensitivity reaction: fever, rash, facial swelling, mouth sores, breathing difficulty
• Severe rash with blistering or peeling skin
• Symptoms of liver problems: yellowing of skin/eyes, dark urine, persistent upper abdominal pain
• New or worsening mood symptoms (rare, but worth acting on quickly)

One sentence of reality: insomnia is one of the complaints I hear most with dolutegravir, and moving the dose to the morning often fixes it.

Common mistakes

These are the errors that most often lead to side effects, anxiety, or loss of viral control.

• Taking Tivicay with antacids or mineral supplements at the same time. Aluminium/magnesium antacids, calcium, and iron can bind dolutegravir in the gut and reduce absorption, which is avoidable with spacing.
• Changing dose timing every day. A shifting schedule creates missed doses; a fixed daily anchor (breakfast, teeth brushing, bedtime) works better.
• Stopping after a rash without urgent clinical advice. Mild rashes happen with many medicines, yet hypersensitivity needs rapid action; the key is prompt assessment, not self-triage.
• Assuming a creatinine rise means kidney failure. Dolutegravir can raise creatinine by transporter effects without reducing true GFR; your clinician will interpret the pattern.
• Not disclosing “non-prescription” medicines. Oxcarbazepine and some other enzyme inducers can reduce dolutegravir levels; interaction screening only works with a full list.

Small habits decide outcomes. Short. Simple. Clear.

Doctor opinions

In HIV clinics, dolutegravir is often chosen because it is potent and has a high barrier to resistance when taken consistently, which can be reassuring for people newly starting antiretroviral therapy. Clinicians also like the dosing flexibility and the fact that it can be taken with or without food, since routine-friendly plans tend to succeed long term. The trade-off is that neuropsychiatric effects (sleep disturbance, headache, sometimes anxiety) can be the reason a patient asks to change, even when viral suppression is excellent. Another pattern doctors watch for is weight change after switching to integrase inhibitors; the cause is not always clear, so diet, lifestyle, and the rest of the regimen are reviewed rather than blaming one tablet by default. Guidance documents used in day-to-day practice (including WHO recommendations and regulator-reviewed product information) stress interaction management and adherence support as the factors that most influence outcomes ^[3].

Frequently asked questions

How fast does Tivicay start lowering HIV viral load?

Dolutegravir begins inhibiting HIV replication from the first doses, but viral load decline is measured over weeks, not days. Many patients see a strong drop by the first follow-up labs, and the goal is sustained suppression with consistent combination therapy. Monitoring schedules vary, yet viral load testing is the objective way to confirm response. WHO guidance for antiretroviral therapy includes integrase inhibitor–based regimens as preferred options in many settings.

Can Tivicay be taken with food?

Yes. Tivicay can be taken with or without food, which makes adherence easier for many people with variable schedules. Food can help if nausea shows up early, while fasting dosing can be simpler for others. The more important point is taking it consistently at the planned time each day. Regulator-reviewed product information summarised by EMA supports this administration flexibility ^[2].

Does Tivicay interact with metformin for diabetes?

Yes, it can. Dolutegravir may increase metformin plasma concentration, which can raise the risk of metformin side effects such as gastrointestinal upset and, in vulnerable patients, lactic acidosis risk considerations. Many prescribers manage this by adjusting metformin dose and watching blood glucose and tolerability after starting dolutegravir. This interaction is described in regulator-reviewed prescribing information and is a standard checkpoint in HIV clinics.

Why is dofetilide listed as a medicine that cannot be combined with Tivicay?

Dofetilide is contraindicated with Tivicay because dolutegravir can increase dofetilide exposure, and dofetilide has a narrow safety margin with potential for serious ventricular arrhythmias. This interaction requires a hard stop because dolutegravir can increase dofetilide exposure and the arrhythmia risk is serious. If a patient needs rhythm control therapy, the cardiology and HIV teams coordinate an alternative plan rather than attempting to co-administer. Regulatory agencies such as EMA include this contraindication in official medicine information.

Is Tivicay used in pregnancy and breastfeeding?

Pregnancy decisions are individualised, and many HIV programs use dolutegravir during pregnancy with appropriate counselling and monitoring, balancing maternal viral suppression with fetal safety considerations. Breastfeeding (lactation) is treated differently across settings because of HIV transmission risk and infant exposure; where safe feeding alternatives exist, many guidelines advise avoiding breastfeeding for women living with HIV. Your HIV team will align the plan with local practice standards and the patient’s clinical context. WHO and national programs provide structured recommendations on ART in pregnancy and postpartum care.

Do you offer anonymous delivery?

Front view

Side view

Back view

Your order will be securely packed and shipped within 24 hours. This is exactly what your package will look like (images of an actual item sent). It has the size and look of a regular private letter (9.4x4.3x0.3 in. or 24x11x0.7 cm) and its contents cannot be seen.

Tivicay and fixed-dose combination tablets

Dolutegravir is also available inside single-tablet regimens, where it is co-formulated with other antiretrovirals. The best-known example is abacavir/dolutegravir/lamivudine (Triumeq), which folds a full regimen into one daily tablet.

Standalone Tivicay stays useful when a regimen needs to be built around individual drugs — for example, to avoid abacavir in people who test HLA-B*5701 positive, or to combine dolutegravir with a different backbone. Your HIV team decides between a single-tablet regimen and a built-up regimen based on resistance history, other medicines, and kidney or liver status.